ImmunoGen Revenue and Competitors
Estimated Revenue & Valuation
- ImmunoGen's estimated annual revenue is currently $127.7M per year.
- ImmunoGen received $173.3M in venture funding in June 2018.
- ImmunoGen's estimated revenue per employee is $337,725
- ImmunoGen's total funding is $55M.
- ImmunoGen's current valuation is $1.4B. (January 2022)
Employee Data
- ImmunoGen has 378 Employees.
- ImmunoGen grew their employee count by 1% last year.
ImmunoGen's People
| Name | Title | Email/Phone |
|---|---|---|
1 | CSO | Reveal Email/Phone |
2 | VP | Reveal Email/Phone |
3 | Chief Scientific Officer | Reveal Email/Phone |
4 | Chief Medical Officer | Reveal Email/Phone |
5 | VP Marketing | Reveal Email/Phone |
6 | VP, Corporate Development | Reveal Email/Phone |
7 | Head Study Startup | Reveal Email/Phone |
8 | VP Biometrics | Reveal Email/Phone |
9 | VP and Chief Accounting Officer | Reveal Email/Phone |
10 | VP, Pharmacovigilance at ImmunoGen | Reveal Email/Phone |
ImmunoGen Competitors & AlternativesAdd Company
| Competitor Name | Revenue | Number of Employees | Employee Growth | Total Funding | Valuation |
|---|---|---|---|---|---|
#1 | $5.2M | 67 | -45% | $107.3M | N/A |
#2 | $0.3M | 2 | 0% | N/A | N/A |
#3 | $5.1M | 33 | 6% | N/A | N/A |
#4 | $11.9M | 77 | -37% | $312.8M | N/A |
#5 | $0.9M | 6 | 0% | N/A | N/A |
#6 | $235M | 300 | -5% | $340.9M | N/A |
#7 | $45.9M | 237 | -7% | $7.6M | N/A |
#8 | $3.9M | 50 | 35% | N/A | N/A |
#9 | $5.4M | 35 | 3% | N/A | N/A |
#10 | $1.6M | 10 | 0% | N/A | N/A |
What Is ImmunoGen?
Targeting a better life for people with cancer is why we get up in the morning. It's not enough to disrupt the progress of someone's cancer; we want to keep cancer from disrupting someone's life. That's why everything we do is about developing the most precise, targeted cancer therapies. We believe this is the best way to get people back to their livesback to living today, tomorrow, and beyond. Because for us, targeting a better now is the only thing that matters. We are a clinical-stage biotechnology company that develops targeted cancer therapeutics using antibody-drug conjugate (ADC) technology. Our lead product candidate, mirvetuximab soravtansine, is in Phase 3 study for FR-positive platinum-resistant ovarian cancer, and Phase 1b/2 testing in combination regimens. Our novel IGN candidates for hematologic malignancies, IMGN779 and IMGN632, are in Phase 1 studies. Learn more about who we are, what we do, and how we do it at www.immunogen.com.
keywords:Biotechnology,Healthcare,Marketing,Pharmaceuticals
$55M
Total Funding
378
Number of Employees
$127.7M
Revenue (est)
1%
Employee Growth %
$1.4B
Valuation
N/A
Accelerator
ImmunoGen News
That's because fast revenue growth can be easily extrapolated to forecast profits, often of considerable size. ImmunoGen's revenue trended up 31...
ImmunoGen, Inc. (NASDAQ:IMGN) Expected to Post Quarterly Sales of $24.35 Million. Posted by admin on Apr 26th, 2022.
The market recently discounted ImmunoGen due to its expectation of Mirvetuximab's SORAYA data. · Contrary to market belief, I view Mirve as a...
Other Companies in Waltham
| Company Name | Revenue | Number of Employees | Employee Growth | Total Funding |
|---|---|---|---|---|
#1 | $100.3M | 387 | 42% | $93M |
#2 | $91.4M | 388 | 21% | $886.5M |
#3 | $134.7M | 399 | 6% | N/A |
#4 | $24.6M | 400 | 96% | N/A |
#5 | N/A | 407 | -1% | $264.9M |
ImmunoGen Funding
| Date | Amount | Round | Lead Investors | Reference |
|---|---|---|---|---|
| 2008-06-24 | $25.0M | Undisclosed | Ziff Asset Management L.P | Article |
| 2009-06-19 | $33.0M | Undisclosed | Oppenheimer and Co Inc | Article |
| 2012-07-13 | $100.0M | Undisclosed | Article | |
| 2016-06-15 | $115.0M | Undisclosed | Article | |
| 2017-06-05 | $30.0M | Undisclosed | Sanofi | Article |
| 2017-10-06 | $Undisclosed | Undisclosed | Jefferies | Article |
| 2018-06-08 | $173.3M | Undisclosed | J.P. Morgan Securities LLC | Article |